Related Experiment Video
Updated: Feb 9, 2026

Photodynamic Therapy with Blended Conducting Polymer/Fullerene Nanoparticle Photosensitizers
Published on: October 28, 2015
A New Photosensitized Oxidation-Responsive Nanoplatform for Controlled Drug Release and Photodynamic Cancer Therapy
Huan-Pu Yeh1, Andrea C Del Valle1, Ming-Chen Syu1
1Department of Biomedical Engineering and Environmental Sciences , National Tsing Hua University , Hsinchu , Taiwan ROC.
Abstract:
Abnormal biochemical alteration such as unbalanced reactive oxygen species (ROS) levels has been considered as a potential disease-specific trigger to deliver therapeutics to target sites. However, in view of their minute variations in concentration, short lifetimes, and limited ranges of action, in situ generation of ROS with specific manipulations should be more effective for ROS-responsive drug delivery. Here we present a new delivery nanoplatform for photodynamic therapy (PDT) with on-demand drug release regulated by light irradiation. Rose bengal (RB) molecules, which exhibit a high yield of ROS generation, were encapsulated in a mixture of chitosan (CTS), poly(vinyl alcohol) (PVA), and branched polyethylenimine ( bPEI) with hydrophobic iron oxide nanoparticles through an oil-in-water emulsion method. The as-prepared magnetic nanoclusters (MNCs) with a tripolymer coating displayed high water dispersibility, efficient cellular uptake, and the cationic groups of CTS and bPEI were effective for RB loading through electrostatic interaction. The encapsulation efficiency of RB in MNCs could be further improved by increasing the amount of short bPEI chains. During the photodynamic process, controlled release of the host molecules (i.e., RB) or guest molecules (i.e., paclitaxel) from the bPEI-based nanoplatform was achieved simultaneously through a photooxidation action sensitized by RB. This approach promises specific payload release and highly effective PDT or PDT combined therapy in various cancer cell lines including breast (MCF-7 and multidrug resistant MCF-7 subline), SKOV-3 ovarian, and Tramp-C1 prostate. In in vivo xenograft studies, the nanoengineered light-switchable carrier also greatly augments its PDT efficacy against multidrug resistant MCF-7/MDR tumor as compared with free drugs. All the above findings suggest that the substantial effects of enhanced drug distribution for efficient cancer therapy was achieved with this smart nanocarrier capable of on demand drug release and delivery, thus exerting its therapeutic activity to a greater extent.
Insights
This study introduces a novel light-activated nanoplatform for cancer therapy. The nanocarrier effectively delivers drugs and enhances photodynamic therapy (PDT) by generating reactive oxygen species (ROS) on demand.
Area of Science:
- Biomedical Engineering
- Materials Science
- Nanotechnology
Background:
- Unbalanced reactive oxygen species (ROS) levels are implicated in disease, but their transient nature limits therapeutic applications.
- In situ generation of ROS offers a more effective strategy for ROS-responsive drug delivery systems.
Purpose of the Study:
- To develop a light-triggered nanoplatform for on-demand drug release and photodynamic therapy (PDT).
- To investigate the efficacy of this nanoplatform in various cancer cell lines and in vivo models.
Main Methods:
- Encapsulation of Rose Bengal (RB) and paclitaxel within magnetic nanoclusters (MNCs) composed of chitosan (CTS), poly(vinyl alcohol) (PVA), and branched polyethylenimine (bPEI).
- Utilized an oil-in-water emulsion method for nanoplatform fabrication.
- Evaluated cellular uptake, drug loading efficiency, and controlled release mechanisms triggered by light irradiation and RB-sensitized photooxidation.
Main Results:
- The prepared MNCs demonstrated good water dispersibility and efficient cellular uptake.
- RB loading efficiency was enhanced by optimizing bPEI chain length.
- Simultaneous controlled release of RB and paclitaxel was achieved upon light irradiation, leading to effective PDT and combined therapy.
- In vivo studies showed augmented PDT efficacy against multidrug-resistant breast cancer xenografts compared to free drugs.
Conclusions:
- The developed light-switchable nanocarrier enables on-demand drug release and delivery, significantly enhancing therapeutic efficacy.
- This smart nanoplatform shows promise for advanced cancer treatment, including PDT and combination therapies, particularly for multidrug-resistant cancers.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drug Therapy
Antianxiety Medications
Drugs Affecting Neurotransmitter Release or Uptake
Targeted Cancer Therapies
There are several types of targeted therapies against...
Pyruvate Oxidation
First, the enzyme pyruvate dehydrogenase removes the carboxyl group from pyruvate and releases it as carbon dioxide. The stripped molecule is then oxidized and releases electrons, which are then picked up by NAD+...
Oxidation Numbers

